YSB Past Earnings Performance
Past criteria checks 0/6
YSB's earnings have been declining at an average annual rate of -51.5%, while the Healthcare industry saw earnings growing at 5.1% annually. Revenues have been growing at an average rate of 27.4% per year.
Key information
-51.5%
Earnings growth rate
-35.9%
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | 27.4% |
| Return on equity | -170.2% |
| Net Margin | -18.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How YSB makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16,972 | -3,189 | 1,717 | 94 |
| 30 Sep 23 | 16,248 | -3,605 | 1,676 | 88 |
| 30 Jun 23 | 15,524 | -4,022 | 1,636 | 83 |
| 31 Mar 23 | 14,899 | -2,755 | 1,625 | 81 |
| 31 Dec 22 | 14,275 | -1,489 | 1,615 | 79 |
| 31 Dec 21 | 10,094 | -494 | 1,273 | 57 |
| 31 Dec 20 | 6,065 | -572 | 886 | 25 |
Quality Earnings: 9885 is currently unprofitable.
Growing Profit Margin: 9885 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 9885's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 9885's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9885 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (13.4%).
Return on Equity
High ROE: 9885 has a negative Return on Equity (-170.24%), as it is currently unprofitable.